What Is Ondansetron (Zofran)? FDA Approval, Licensing and Reimbursement in Türkiye

• FDA Approval: Yes (first approval date: January 4, 1991)
• Brand Name: Zofran (original), also sold under generic names such as Ondansetron-Teva and Ondansetron Sandoz
• Active Ingredient: Ondansetron hydrochloride
• Routes of Administration: Oral tablets (film-coated or dispersible), oral solution, intravenous (IV) injection, intramuscular (IM) injection, sublingual tablets
• Class: 5-HT₃ (serotonin) receptor antagonist (antiemetic)
• Category: Prevention of nausea and vomiting (antiemetic drug)
• Manufacturer: Originally developed by GlaxoSmithKline (formerly Glaxo Wellcome); now manufactured by many generic companies.
• Distribution in Türkiye: Marketed under licenses held by various companies. Brands include Zofran, Ondavell, Ondaset, Vomidon, and Emedron. Prescription-only (standard white prescription), with SGK reimbursement depending on indication.
• Approved Cancers: Ondansetron does not directly treat cancer; it prevents chemotherapy-induced nausea and vomiting.

What Is Ondansetron and How Does It Work?

Ondansetron prevents and treats nausea and vomiting, particularly after chemotherapy, radiotherapy, or surgery. Pharmacologically, it is a serotonin (5-hydroxytryptamine) receptor antagonist, specifically a 5-HT₃ receptor antagonist. It blocks transmission of nausea- and vomiting-inducing signals to the relevant brain centers.

Ondansetron is widely used to reduce emetogenic (vomiting-inducing) adverse effects during cancer treatment, which can substantially impair quality of life.

How Does It Work?

Its main effect is to block the neurotransmitter serotonin (5-HT) through the following mechanisms:

• Peripheral Effect (Gastrointestinal Tract): Stimuli such as chemotherapy or radiotherapy increase serotonin release from enteroendocrine cells in the intestinal mucosa. Serotonin activates 5-HT₃ receptors on the vagus nerve, triggering the vomiting reflex. Ondansetron blocks these receptors and prevents this process.
• Central Effect (Brain): 5-HT₃ receptors are also present in the area postrema and nucleus tractus solitarius, regions associated with the vomiting center. Blocking these receptors provides central control of nausea and vomiting.

FDA (US Food and Drug Administration) Approval History

• January 4, 1991: The FDA approved intravenous (IV) ondansetron (Zofran) to prevent chemotherapy-induced nausea and vomiting, including with highly emetogenic drugs such as cisplatin.
• December 31, 1992: The FDA approved the oral tablet formulation for chemotherapy-induced nausea and vomiting. Easier home administration encouraged wider use.
• July 31, 1997: FDA approval was granted for postoperative nausea and vomiting, allowing use after general anesthesia.
• 2006 Orally Disintegrating Tablet (ODT): The FDA approved the Zofran ODT formulation, which dissolves on the tongue and is easier to take for patients prone to vomiting.
• March 2011: The FDA issued a safety warning about QT prolongation and arrhythmias such as torsades de pointes. ECG monitoring was recommended because risk increased with high-dose IV formulations.
• June 2012: The FDA recommended removing the 32 mg IV dose from the market. This high dose was prohibited because of adverse cardiac rhythm effects.

Licensing in Türkiye

Ondansetron is licensed by Türkiye's Ministry of Health Turkish Medicines and Medical Devices Agency (TİTCK) and marketed under different names and formulations.

Therapeutic Indications

• Chemotherapy-Induced Nausea and Vomiting: Prevention and treatment of nausea and vomiting caused by cytotoxic chemotherapy.
• Radiotherapy-Induced Nausea and Vomiting: Prevention and treatment of nausea and vomiting caused by radiotherapy.
• Postoperative Nausea and Vomiting: Prevention and treatment of nausea and vomiting after surgery.

Reimbursement

The Social Security Institution (SGK) reimburses ondansetron-containing medicines for specified indications, including nausea and vomiting associated with chemotherapy, radiotherapy, or surgery. 

Current Prices: 

• Zofran 8 mg, 6 tablets: 97.50 TL
• Zofran 4 mg/2 ml solution for injection (1 ampoule): 95.11 TL
• Zofran 8 mg/4 ml solution for injection (1x4 ampoules): 104.14 TL
• Zofer 4 mg, 10 tablets: 400.97 TL
• Onzyd 4 mg, 10 orally disintegrating tablets: 798.34 TL
• Onzyd 8 mg, 10 orally disintegrating tablets: 691.98 TL
• Ondaren 4 mg/2 ml IV solution for injection (1 ampoule): 132.81 TL
• Ondaren 8 mg/4 ml IV solution for injection (1 ampoule): 328.62 TL

Mechanisms of Resistance

• Desensitization of 5-HT₃ Receptors: Prolonged or repeated use may reduce serotonin (5-HT₃) receptor sensitivity through downregulation (fewer receptors) or altered receptor conformation. The desired antiemetic effect may then fail despite drug binding.
• Activation of Alternative Vomiting Pathways: Nausea and vomiting involve more than serotonin. Dopamine (D₂), neurokinin-1 (NK1), acetylcholine, and histamine pathways can also trigger the reflex. If these become active, ondansetron, a 5-HT₃ antagonist, may be insufficient alone. Such multipathway vomiting can occur particularly with highly emetogenic chemotherapy.
• Pharmacokinetic Factors: Malabsorption, differences in liver metabolism, particularly involving CYP2D6, or rapid elimination may result in inadequate blood concentrations and reduced efficacy.
• Genetic Polymorphisms: Individual differences in 5-HT₃ receptor genes may alter sensitivity to ondansetron. Some people have genetically reduced receptor sensitivity or a different receptor structure and may not respond.
• Drug Tolerance: Some patients may develop tolerance over time, making the same dose ineffective and creating a need for higher doses. This is rare and generally associated with activation of alternative mechanisms.

Absorption

Ondansetron is rapidly absorbed orally. Bioavailability is approximately 60% because of first-pass metabolism, with maximum plasma concentrations generally reached in 1.5–2 hours. Orally disintegrating tablets (ODTs) and injections may provide faster, more predictable absorption than conventional oral tablets.

Distribution

Ondansetron distributes widely into body fluids and tissues, with a high volume of distribution and effective concentrations particularly in the liver, intestines, and central nervous system. Plasma protein binding is approximately 70%, contributing to a profile that reaches tissue targets effectively.

Metabolism

The drug is metabolized mainly in the liver through:

• CYP3A4,
• CYP2D6,
• and CYP1A2.

These pathways produce inactive metabolites. Genetic differences, particularly involving CYP2D6, may alter ondansetron's effect and duration.

Elimination

Elimination occurs through urine and feces. Approximately 5% is excreted unchanged in urine; the rest is eliminated as metabolites.

Elimination half-life:

• Approximately 3–6 hours in adults,
• potentially longer in older people or those with liver impairment.

Dose Range

• Chemotherapy-Induced Nausea and Vomiting

Adults: oral tablets or IV, 8 mg administered 30 minutes before chemotherapy, followed by another 8 mg 8 hours later. For the next 1-2 days, 8 mg may continue 2 times daily (every 12 hours).

Children (6 months – 17 years): IV dose 0.15 mg/kg within 15 minutes before chemotherapy, repeated at 4 and 8 hours. Maximum single dose: 16 mg (generally applicable to children >40 kg).

• Radiotherapy-Induced Nausea and Vomiting

Adults: 8 mg orally approximately 1–2 hours before radiotherapy, repeated 2–3 times daily (every 8 hours) if necessary.

• Postoperative Nausea and Vomiting

Adults: oral 16 mg approximately 1 hour before anesthesia.

IV: a single 4 mg dose during or after surgery.

Children (≥1 month): IV 0.1 mg/kg (maximum 4 mg) after surgery. A single dose is generally sufficient.

Drug Interactions

• Interactions with QT-Prolonging Drugs: Ondansetron can prolong cardiac QT. Relevant drugs include amiodarone and sotalol (antiarrhythmics), macrolides such as erythromycin or clarithromycin, fluoroquinolones such as levofloxacin or moxifloxacin, antipsychotics such as haloperidol or ziprasidone, and methadone. If combinations are necessary, monitor QT by ECG.
• Interactions with Serotonergic Drugs (Serotonin Syndrome Risk): Ondansetron may indirectly affect serotonin signaling. Relevant drugs include SSRIs (sertraline, fluoxetine, paroxetine), SNRIs (venlafaxine, duloxetine), MAO inhibitors (selegiline, moclobemide), triptans such as sumatriptan, tramadol, linezolid, and lithium. Serotonin syndrome may cause fever, muscle rigidity, agitation, or seizures.
• CYP Enzyme Inhibitors and Inducers: Ondansetron is metabolized by hepatic CYP3A4, CYP2D6, and CYP1A2. Drugs affecting these enzymes may alter its levels. Ketoconazole or itraconazole (antifungals), erythromycin, or grapefruit juice may increase its effect. Rifampin, carbamazepine, phenytoin, or dexamethasone may reduce it.
• Contraindicated with Apomorphine: Apomorphine + ondansetron may cause severe hypotension and loss of consciousness. They must not be used together.
• Interactions with Anesthetics and Sedatives: Although generally well tolerated, ondansetron with some anesthetic agents may cause blood pressure instability and rare bradycardia.
• Use caution in patients at risk of QT prolongation, including those with electrolyte imbalances or heart disease.
• Increase monitoring with other serotonergic drugs.
• Dose adjustment may be needed with drugs affecting hepatic enzymes.

Points Requiring Attention

• QT Prolongation and Cardiac Arrhythmias: Ondansetron may prolong QT by affecting cardiac electrical conduction, potentially causing serious, life-threatening torsades de pointes. Use caution in patients with heart disease, hypokalemia or hypomagnesemia, or genetic susceptibility to QT prolongation. High-dose IV administration is particularly risky.
• Liver Impairment: Ondansetron is metabolized in the liver and may accumulate in severe hepatic dysfunction. The maximum daily dose should therefore be limited to 8 mg.
• Serotonin Syndrome Risk: Concurrent serotonergic drugs, such as SSRIs, SNRIs, MAO inhibitors, or tramadol, increase serotonin syndrome risk. Symptoms include agitation, sweating, muscle spasms, fever, and altered consciousness. Monitor patients carefully during concurrent use.
• Allergic Reactions: Rare hypersensitivity reactions may include rash, urticaria, bronchospasm, or anaphylaxis. It is contraindicated in patients with previous reactions to ondansetron or similar 5-HT₃ antagonists.
• Pregnancy and Breastfeeding: Pregnancy safety data are limited. Some studies associate first-trimester use with congenital defects. Use during pregnancy only if the benefit outweighs the potential risk. During breastfeeding, careful assessment is necessary because it may enter breast milk.
• Use in Children and Older People: Pediatric doses require careful adjustment, with particular caution when using injections in younger children. Older people require closer monitoring of cardiac effects and elimination.
• Concurrent Apomorphine Use: Ondansetron must never be combined with apomorphine because severe hypotension and loss of consciousness may occur.

Adverse Reactions

• Headache 10–16%
• Constipation 6–11%
• Fatigue 4–7%
• Dizziness 4–6%
• Diarrhea 2–5%
• Cardiac arrhythmia (including QT prolongation) 1–3%
• Bradycardia (slow heartbeat) 1–2%
• Increased transaminases (liver enzymes) 1–2%
• Flushing / vasodilation less than 1%
• Serotonin syndrome <1%
• Dyspnea (shortness of breath) <1%
• Confusion <1%
• Itching / rash <1%
• Hypersensitivity reactions (urticaria, anaphylaxis) <0.1%
• Seizures (convulsions) <0.1%
• Transient visual disturbances (particularly with IV administration) <0.1%